BidaskClub downgraded shares of Paratek Pharmaceuticals (NASDAQ:PRTK) from a sell rating to a strong sell rating in a report published on Tuesday.

Other analysts also recently issued reports about the company. Zacks Investment Research upgraded Paratek Pharmaceuticals from a hold rating to a buy rating and set a $16.00 price target for the company in a research report on Friday, February 16th. Cantor Fitzgerald set a $50.00 price target on Paratek Pharmaceuticals and gave the stock a buy rating in a research report on Wednesday, January 3rd. Finally, HC Wainwright raised their price target on Paratek Pharmaceuticals from $43.00 to $55.00 and gave the stock a buy rating in a research report on Friday, March 2nd. Two analysts have rated the stock with a sell rating, one has given a hold rating and seven have given a buy rating to the stock. The company has a consensus rating of Buy and a consensus target price of $40.00.

Shares of PRTK opened at $10.60 on Tuesday. The firm has a market capitalization of $349.02, a P/E ratio of -3.21 and a beta of 0.43. Paratek Pharmaceuticals has a 52-week low of $10.10 and a 52-week high of $29.00. The company has a quick ratio of 9.56, a current ratio of 9.56 and a debt-to-equity ratio of 0.72.

Paratek Pharmaceuticals (NASDAQ:PRTK) last issued its quarterly earnings results on Thursday, March 1st. The specialty pharmaceutical company reported ($0.78) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.75) by ($0.03). The company had revenue of $5.07 million during the quarter, compared to the consensus estimate of $5.00 million. Paratek Pharmaceuticals had a negative return on equity of 93.16% and a negative net margin of 706.00%. sell-side analysts anticipate that Paratek Pharmaceuticals will post -3.48 earnings per share for the current fiscal year.

In other Paratek Pharmaceuticals news, CFO Douglas W. Pagan sold 5,237 shares of the stock in a transaction on Monday, April 9th. The stock was sold at an average price of $12.70, for a total value of $66,509.90. Following the sale, the chief financial officer now owns 77,083 shares in the company, valued at $978,954.10. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, VP Adam Woodrow sold 14,333 shares of the stock in a transaction on Tuesday, February 6th. The stock was sold at an average price of $13.87, for a total value of $198,798.71. Following the completion of the sale, the vice president now owns 62,367 shares in the company, valued at approximately $865,030.29. The disclosure for this sale can be found here. In the last quarter, insiders sold 68,385 shares of company stock worth $925,282. Insiders own 4.90% of the company’s stock.

A number of hedge funds have recently added to or reduced their stakes in the business. MetLife Investment Advisors LLC purchased a new stake in Paratek Pharmaceuticals in the fourth quarter worth $185,000. LPL Financial LLC increased its stake in shares of Paratek Pharmaceuticals by 13.0% during the fourth quarter. LPL Financial LLC now owns 44,575 shares of the specialty pharmaceutical company’s stock valued at $798,000 after buying an additional 5,125 shares during the period. TIAA CREF Investment Management LLC increased its stake in shares of Paratek Pharmaceuticals by 43.5% during the fourth quarter. TIAA CREF Investment Management LLC now owns 91,711 shares of the specialty pharmaceutical company’s stock valued at $1,642,000 after buying an additional 27,796 shares during the period. Raymond James & Associates increased its stake in shares of Paratek Pharmaceuticals by 109.6% during the fourth quarter. Raymond James & Associates now owns 24,157 shares of the specialty pharmaceutical company’s stock valued at $432,000 after buying an additional 12,632 shares during the period. Finally, Guggenheim Capital LLC increased its stake in shares of Paratek Pharmaceuticals by 47.7% during the fourth quarter. Guggenheim Capital LLC now owns 71,665 shares of the specialty pharmaceutical company’s stock valued at $1,284,000 after buying an additional 23,142 shares during the period. Institutional investors and hedge funds own 74.61% of the company’s stock.

Paratek Pharmaceuticals Company Profile

Paratek Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics based upon tetracycline chemistry in the United States. Its lead product candidates include omadacycline, an intravenous and oral antibiotic for use as a monotherapy antibiotic for acute bacterial skin and skin structure infections, community-acquired bacterial pneumonia, urinary tract infections, and other community-acquired bacterial infections; and Sarecycline, a tetracycline-derived compound designed for use in the treatment of acne and rosacea.

Analyst Recommendations for Paratek Pharmaceuticals (NASDAQ:PRTK)

Receive News & Ratings for Paratek Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Paratek Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.